Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 2,723,912 shares, a growth of 45.6% from the October 15th total of 1,871,370 shares. Based on an average daily volume of 832,548 shares, the days-to-cover ratio is currently 3.3 days. Approximately 6.5% of the shares of the stock are sold short.
Institutional investors have recently added to or reduced their stakes in the company. Bard Associates Inc. bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $189,000. Essex Investment Management Co. LLC raised its position in shares of Eyepoint Pharmaceuticals by 65.0% during the third quarter. Essex Investment Management Co. LLC now owns 134,509 shares of the company’s stock valued at $480,000 after buying an additional 52,977 shares during the last quarter. FineMark National Bank & Trust bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $118,000. Creative Planning bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $162,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $2,339,000. Hedge funds and other institutional investors own 62.85% of the company’s stock.
Shares of NASDAQ:EYPT opened at $2.30 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 1.48. Eyepoint Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $3.94. The company has a market cap of $172.87 million, a price-to-earnings ratio of -3.97 and a beta of 1.73.
Several brokerages have weighed in on EYPT. Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. ValuEngine raised shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 29th. HC Wainwright set a $3.00 price target on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 27th. Finally, B. Riley lifted their price target on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Eyepoint Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $5.50.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.
Further Reading: Earnings Per Share
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.